Related Experiment Video
Updated: Apr 10, 2026
08:15
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
1.0K
The Dark Side of Blocking RAS in Diabetic Patients with Incipient or Manifested Nephropathy
D Bolignano1, A Pisano1, G Coppolino2
1CNR - Institute of Clinical Physiology, Reggio Calabria, Italy.
Summary
Renin-angiotensin system (RAS) inhibitors may not benefit all diabetic patients with hypertension. Personalized treatment is recommended due to potential null effects and risks like hyperkalemia.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Renin-angiotensin system (RAS) inhibitors are standard for hypertensive diabetic patients with renal damage.
- Their use is based on assumed cardiovascular and renal benefits, including blood pressure reduction and pleiotropic effects.
Purpose of the Study:
- To review evidence on the negative or null effects of RAS inhibitors in diabetic patients.
- To advocate for personalized RAS inhibitor use based on individual patient characteristics.
Main Methods:
- Review of large randomized controlled trials.
- Analysis of independent meta-analyses.
- Synthesis of evidence on clinical outcomes and adverse events.
Main Results:
- Data suggest that cardiovascular and renal benefits of RAS inhibitors in diabetics may not be as significant as believed.
- Hyperkalemia risk is a notable concern in diabetic patients using these drugs.
- Evidence supports questioning the universal application of RAS inhibitors in all diabetic patients.
Conclusions:
- The generalized use of RAS inhibitors in diabetic patients warrants re-evaluation.
- A personalized approach, considering individual patient factors, is crucial for optimizing treatment outcomes.
- Further research may refine guidelines for RAS inhibitor therapy in diabetes.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
01:16Antihypertensive Drugs: Action of Diuretics
2.8K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.8K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
2.3K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
2.3K
01:22Heart Failure Drugs: Diuretics
1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K